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Purpose:  To explore the ability of gastrointestinal ultrasound (GIUS) to separate patients in 
endoscopic remission from patients with active disease in a heterogenous hospital cohort with 
CD.  
 
Material and Methods: 145 CD patients scheduled for ileocolonoscopy were prospectively 
included. The endoscopic disease activity was quantified using the Simple Endoscopic Score 
for Crohn’s disease (SES-CD), and mucosal healing was strictly defined as SES-CD=0. 
Ultrasound remission was defined as wall thickness <3 mm (<4 mm in the rectum). 
Additionally, SES-CD was compared to colour Doppler, Harvey Bradshaw’s index (HBI), C-
reactive protein (CRP) and calprotectin. 23 patients were examined by two investigators for 
interobserver assessment. 
 
Results: 102 had active disease and 43 patients were in remission. GIUS yielded a sensitivity 
of 92.2% and specificity of 86% for wall thickness and sensitivity 66.7% and specificity 
97.7% for colour Doppler. For HBI sensitivity was 34.3% and specificity 88.4%, CRP 
sensitivity 35.7% and specificity 82.9% and calprotectin sensitivity 55.9 % and specificity 
82.1%. The interobserver analysis revealed excellent agreement for wall thickness- (k=0.90) 
and colour Doppler (k=0.91) measurements.  
 
Conclusion: GIUS has a high sensitivity for detecting endoscopic activity. Accordingly, 
bowel ultrasound has the potential to reduce the number of routine ileocolonoscopies in 
patients with CD. 
 
 








Crohn’s disease (CD) is characterized by alternating periods of remission and disease flare-
ups, requiring subsequent adjustments of medical therapy. However, there is a lack of 
correlation between patients’ symptoms and inflammatory activity [1], putting patients at risk 
of receiving wrong treatment. Persistent inflammation may be present during clinical 
remission allowing for development of complications, ultimately leading to irreversible bowel 
damage [2]. Consequently, new treatment goals have emerged from symptomatic control to 
objective endpoints, where mucosal healing (MH) evaluated by ileocolonoscopy is considered 
the main therapeutic target. Current evidence suggests that patients achieving MH experiences 
less hospitalization, relapse rates, surgery and bowel damage, which may alter the natural 
disease course [3]. 
Endoscopic remission is usually defined as absence of ulcerations at ileocolonoscopy or as a 
score of 0-2 using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) [4]. However, 
previous work suggest that patients with complete absence of endoscopic inflammation 
reflected by a SES-CD score of 0 points have the best prognosis [5]. On the downside, 
ileocolonoscopy is invasive, resource intensive, and patients are reluctant to undergo frequent 
examinations. Thus, non-invasive markers for measuring disease status are warranted. 
Faecal calprotectin is a well-established biomarker of intestinal inflammation that correlates 
well with endoscopy and may be useful in discriminating between active and inactive disease 
[6]. Still, higher accuracies are achieved in ulcerative colitis than CD [7] as well as in colonic 
versus small bowel CD [8]. 
Cross-sectional imaging modalities such as computed tomography (CT), magnetic resonance 
imaging (MRI) and ultrasound (US) are important tools in CD assessment, enabling detection 
of location, complications and extent, as well as disease activity evaluation [9]. Due to radiation 
exposure of CT, it is recommended that MRI and US are used in follow-up examinations [9]. 
Recent studies demonstrate that MRI is accurate for evaluating ulcer healing and endoscopic 
remission [10], and may thus gain further importance in the treat-to-target era. Still, it is 
resource intensive, requires specific preparations and has relatively low availability. 
Ultrasound is non-invasive, well tolerated by patients and can be performed bedside, making 
the modality well suited for repeated examinations. As numerous follow-up examinations for 
monitoring disease status are needed, gastrointestinal ultrasound (GIUS) might be an attractive 
modality. GIUS has high diagnostic accuracy for detecting CD [11], where increased bowel 
wall thickness (BWT) is the most important and common ultrasonographic parameter [12]. 
Previous studies showed that ultrasonographic changes during medical treatment correlates 
with endoscopic response and may provide measurements of MH [13-15]. These studies 
evaluate post-therapeutic changes in patients with active CD, thus, the usefulness of 
ultrasonography in different disease statuses remains unknown. In this study, we aimed to 
explore the ability of GIUS to separate patients in endoscopic remission from patients with 
active disease in a heterogeneous hospital cohort with CD. 
Material and methods 
Patients and design:  
145 patients with established CD were prospectively recruited in a single-centre cross-
sectional study, from 2015 to 2019. Each patient was scheduled for ileocolonoscopy as part of 
routine work at the hospital. Included patients underwent clinical scoring, blood and stool 
sampling as well as ultrasound examination. Exclusion criteria were age <18 years, 
pregnancy, previous colectomy, isolated disease in the upper GI tract or ongoing 
gastroenteritis. 
 
Clinical and biochemical tests  
Patient history, demographics and phenotype, according to the Montreal classification [16] , 
were recorded on each study participant. Harvey Bradshaw Index (HBI) [17] was used to 
evaluate clinical disease activity. The biochemical markers haemoglobin (g/dL), leucocyte- 
(109/L) and platelet (109/L) count, C-reactive protein (CRP) (mg/L) and albumin (g/L) were 
measured from blood samples, while stool samples were analysed for calprotectin (mg/kg). 
The biochemical tests were sampled within one week prior to or after the ultrasound 
examination. Clinical remission was considered as HBI <5 points, while calprotectin < 50 
mg/kg and CRP <5 mg/L were defined as biochemical remission. 
 
Endoscopy  
Ileocolonoscopy was performed as part of standard care by 20 endoscopists with 
approximately 1-30 years of experience. Disease activity measurements were assessed using 
the SES-CD. This scoring system evaluates the severity of CD-lesions by creating a numerical 
value of 0-3 in four parameters (ulcer size, ulcerated surface, affected surface and stenosis), 
summarized in five bowel segments (rectum, left colon, transverse colon, right colon and the 
terminal ileum). Then, segmental- and total endoscopic activity can be quantified [18]. 
Although endoscopic remission is commonly considered as SES-CD 0-2 [4], validated scores 
of MH are lacking [19]. Furthermore, as long-term prognosis seems to improve when there is 
no macroscopic inflammation [5], we used a strict definition of endoscopic remission as SES-
CD=0. In addition, all patients were scored for the presence or absence of ulcerations.  
 
 
Ultrasound examination  
The ultrasound examinations were performed within two weeks prior to or after the 
endoscopic procedure, with no treatment alterations between the examinations. 
Ultrasonography was not performed during bowel preparation or just after ileocolonoscopy as 
the intestine usually collapses, making standardization more complicated. Patients were 
examined after an overnight fast with no further bowel preparations. GIUS was performed 
using a Logiq E9 ultrasound scanner (GE Healthcare, Milwaukee, Wisconsin, USA), 
equipped with a curvilinear transducer (C1-6, 1-6 MHz) for abdominal overview and a linear 
probe (9L, 5.5-9 MHz) for detailed examinations of the bowel wall. The GIUS examinations 
were performed by two investigators with 2 and 13 years of experience, and interobserver 
assessments were performed in a subgroup of the included patients. 
The GIUS examinations were performed on bowel segments available for ileocolonoscopy. 
The examination of the large bowel was performed by scanning systematically from the 
terminal ileum and further distally in longitudinal section, as recommended in international 
guidelines [20]. All BWT measurements were performed perpendicular to the anterior wall in 
longitudinal section, measured from the start of the hypoechoic proper muscle layer to the end 
of the hypoechoic mucosal layer [20], and two representative measurements were averaged. 
Remission was defined as a BWT <3 mm in both colon and terminal ileum (Fig.1) [12], while 
a cut-off of <4 mm was used in the rectum. 
Colour Doppler was performed only on intestinal segments with pathological wall thickness. 
The velocity scale was adjusted to 5 cm/s for detection of vessels with low blood flow 
velocities. Gain was increased until flash artefacts occurred and then lowered until the 
artefacts disappeared. The acquisition was performed during patient breath-hold. Colour 
Doppler was evaluated by counting the number of Doppler signals per cm2 using a modified 
version of [21], where 0-1, 2-5 and >5 signals were scored as 0, 1 and 2, respectively. 
Remission was defined as a Doppler score of 0, while activity defined as 1-2. 
The study investigators were blinded to the results from the corresponding ileocolonoscopy 
but knew the Montreal classification and HBI. 
 
Statistics  
Demographical data were analysed using descriptive statistics and tested for normality by 
inspecting histograms as well as using the Shapiro-Wilk test. Comparison between patients in 
endoscopic remission and activity was performed using the Student’s T-test or the Mann-
Whitney U-test for continuous variables, while Chi-square- and Fischer exact test were used 
for categorical variables. Diagnostic accuracy of GIUS, CRP, calprotectin and HBI were 
calculated in terms of sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) and total accuracy. Further, evaluation of interobserver agreement as 
well as concordance between endoscopy and clinical-, biochemical- and ultrasonographic 
parameters were performed using Cohen’s kappa. Kappa statistics considers the amount of 
agreement that may occurred by chance, interpreted as poor if <0, slight if 0-0.2, fair if 0.21-
0.4, moderate if 0.41-0.6, substantial if 0.61-0.8, and excellent if >0.8 [22]. The agreement 
between GIUS and ileocolonoscopy was evaluated per patient. Finally, the BWT and colour 
Doppler measurements were correlated with SES-CD in the corresponding segments using 
Spearman Rank. The level of significance was p<0.05. All statistical analyses were performed 
using SPSS software version 25 (IBM Inc., Armonk, NY, USA). 
 
Ethical consideration 
The study was approved by the Regional Ethics Committee for Medical and Health Research 
in Western Norway, and patients gave written informed consent prior to participation. 
Results  
102 patients had active disease and 43 patients were in endoscopic remission. There were no 
significant differences in demographics between the activity- and remission groups, except for 
CRP, calprotectin and HBI (Tab. 1), as well as disease behaviour and previous surgery (Tab. 
2). There were significant differences  (p<0.001) (Student’s T test) between the thickest wall 
section in the activity group (5.3 mm ± 1.7 SD) and each segment in the remission group 
(ileum: 2.0 mm ± 0.7 SD, right colon: 1.3 mm ± 0.4 SD, transverse colon: 1.3 mm ± 0.5 SD, 
left colon 1.7 mm ± 0.7 SD, rectum: 2,6 mm ± 0.6 SD). Further patient characteristics are 
presented in Tab. 1 and 2. 
Ultrasonographic measurements of BWT >3mm yielded a sensitivity of 92.2% and a 
specificity of 86% to detect endoscopic activity. By increasing the threshold to >4mm BWT, a 
sensitivity of 80.4% and specificity of 90.7% was found. Colour Doppler measurements on 
pathologically thickened bowel walls provided a sensitivity of 66.7% and specificity of 
97.7%. A sub-analysis using presence or absence of ulcerations as endoscopic criterion 
revealed a sensitivity of 92% and specificity of 56.5% for BWT >3 mm. Further results are 
presented in Tab. 3. 
There were 14 mismatches between GIUS and ileocolonoscopy of which 8 were false 
negatives (median BWT 2.1 mm, range 1.4 – 2.8 mm). False negative results were due to 
small aphthous lesions in the terminal ileum in most cases (5/8) each scored as SES-CD=3, 
one patient had aphthous lesions and oedema in the terminal ileum (1/8) scored as SES-
CD=6, while erythema and faded vascular pattern in colon were present in two patients (2/8) 
scored as SES-CD=1 and 6.  
Further, six false positive results were found (median BWT 4.4 mm, range 3.3 – 5.5 mm), of 
which four located in the terminal ileum (4/6) and two in the colon (2/6). In the terminal 
ileum, two were considered as mild active lesions, while the remaining two were interpreted 
as chronic changes after surgical resection in the physicians’ report although BWT exceeded 3 
mm. The false positive results of the colon (2/6) where considered as mild active lesions. 
However, all patients with isolated thickening of the colonic wall (n=18) were correctly 
classified by faecal calprotectin.  
The agreement between ileocolonoscopy and ultrasound wall thickness was substantial with a 
kappa value of 0.772. Corresponding values between endoscopy and colour Doppler, HBI, 
CRP and calprotectin were 0.53, 0.16, 0.13 and 0.30, respectively (Tab. 3). 
The correlation analysis revealed good correlation coefficients between the SES-CD and 
BWT (r=0.69, p<0.001), as well as between SES-CD and colour Doppler (r=0.64, p<0.001).  
23 patients were independently examined by two investigators, and the interobserver analysis 





Our principal finding suggests that wall thickness measured with GIUS is an accurate 
surrogate marker of endoscopic activity (Fig. 2). The usefulness in daily life is further 
demonstrated, as real-world data with patients at different disease stages were included. 
These results are in concordance with previous reports [11,13,23,24], even if there are some 
differences in design, ultrasound thresholds and reference standard. To our knowledge, this is 
the first study comparing the accuracy of BWT measured by GIUS with strictly defined 
endoscopic remission as SES-CD=0. A recent study by Allocca et al. [24] demonstrated that 
GIUS achieved high sensitivity (92%) and specificity (100%) in evaluating disease activity 
defined as the presence of ulcerations >5 mm. Although revealing similar results, the studies 
are not directly comparable as various reference standards were used. Moreover, the patient 
populations may differ as their study participants were recruited from a tertiary reference 
centre. Furthermore, Ripolles et al. [23] demonstrated high positive predictive values for 
BWT (88.4%) and colour Doppler (97%) to detect endoscopic activity. Although similarities 
exist, the studies only partly correspond as they used different bowel wall cut-off, endoscopic 
reference standard (presence and absence of ulcerations) and analysed the diagnostic accuracy 
per segment. Thus, our results may add to the existing body of evidence as we demonstrate 
that GIUS is highly accurate to separate remission from minimal endoscopic inflammation.  
We found a lower specificity of GIUS than previously reported in the latest meta-analysis 
[11], which could be due to different definitions of endoscopic activity and patient 
populations. By increasing the threshold for sonographic activity to 4 mm, a higher specificity 
was found at the expense of decreased sensitivity and overall accuracy. Although reducing 
over-diagnosing, patients are then at risk of being undertreated. Therefore, a threshold of 3 
mm seems to be an appropriate compromise with high sensitivity as well as acceptable 
specificity. Furthermore, we found high positive predictive values for all included tests with 
BWT (3 mm) and colour Doppler being the highest. However, neither ultrasonography nor 
clinical nor biochemical tests achieved sufficient negative predictive values. 
Regular follow-up examinations of patients in remission are recommended for early detection 
of relapse, requiring escalation of treatment [25]. At outpatient clinics, decision-making is 
usually limited to clinical assessment accompanied by biochemical samples. Clinical 
symptoms do not sufficiently measure underlying inflammation [1] while CRP is limited by 
poor sensitivity [7] and increases in other inflammatory conditions as well. Faecal calprotectin 
is useful for initial diagnosis and follow-up of CD, and may provide better guidance for 
treatment decisions compared to symptom-based management [25]. Still, faecal calprotectin is 
limited by reduced specificity when using common cut-off values [7], and in the small 
intestine, it may not sufficiently reflect the true severity of the inflammation. Thus, it should 
be interpreted with caution [7]. In our study, the majority of patients had only terminal ileitis, 
which could explain why we found a surprisingly low sensitivity for calprotectin. However, 
higher accuracies were obtained in a subgroup-analysis on patients with colonic affection, 
confirming that it is more suitable in distal disease. Its optimal use seems to be in monitoring 
of disease activity, where repeated samples from the same patient are evaluated. However, 
patient reluctance for providing repeated stool samples limits its utility. This problem was 
clearly demonstrated in this study, as patient compliance on delivering faecal samples was 
poor. In contrast, focused ultrasound examination of the bowel is feasible in the out-patient 
clinic, and may add important contributions to the overall assessment and clinical decision 
making [26]. 
Previous work suggest that colour Doppler sonography or contrast-enhanced ultrasound 
(CEUS) is useful for detection and evaluations of disease activity [23,27,28]. Even though 
CEUS is found to be reliable for disease activity classification [23], the technique holds 
several limitations leading to reduced reproducibility [29], making comparison between 
different US vendors difficult [30]. Colour Doppler sonography is well suited for activity 
evaluation and classification [12], with high positive predictive value. However, absence of 
Doppler signals is found to have low negative predictive value [23,28], which may be due to 
insensitivity of equipment as well as reduced sensitivity in patients with increased body mass 
index or when measuring at increased depths [20]. Similar results regarding PPV and NPV of 
Doppler sonography were found in the present study. Finally, both colour Doppler and CEUS 
measurements are usually performed on pathologically thickened bowel walls, increasing the 
pre-test probability for activity. Thus, these methods seem more useful for disease activity 
quantification, while BWT measurements seems better suited for determining whether 
patients are in remission or not. False negative results were due to small aphthous lesions 
(Fig. 3) in quite a few cases (5/8). Bowel wall oedema is a prerequisite for detecting 
inflammatory activity on ultrasonography and explains why these changes were not detected. 
The clinical and prognostic significance of aphthous ulcers without oedema is not clear but 
may indicate a milder form of disease. 
Measurements of BWT in collapsed colon segments could lead to overestimation and false 
positive results and should be interpreted with caution [20]. Still, all patients with increased 
BWT limited to the colonic wall were correctly classified by faecal calprotectin. Thus, we 
suggest that for patients with suspected affection of the colon on GIUS, a secondary test of 
calprotectin may be appropriate as specificity seems to improve. The false positive results 
located in the terminal ileum were interpreted as mild active lesions and chronic changes after 
surgery. Biopsies were only performed in three patients, of which all had normal histology. 
A key question regarding biologics is when to discontinue treatment [25]. The best patient 
outcome is achieved when there is no macroscopic evidence of inflammatory activity (SES-
CD or Crohn Disease Endoscopic Index of Severity (CDEIS) = 0) [5,31]. GIUS appears 
accurate for separating active and inactive disease but does not alone provide the clinician 
with the confidence to make the decision to discontinue treatment. Our data suggests that 
patients with active disease on GIUS do not need an ileocolonoscopy as there are few false 
positives. By including calprotectin in patients with colitis on GIUS, the amount of false 
positive results is further reduced. Patients with ileocolonic disease and normal findings on 
ultrasound should, however, be examined with ileocolonoscopy to exclude false negatives. 
Nevertheless, as the present data are based on a heterogenous CD population, future studies 
are needed to compare the value of ultrasound with ileocolonoscopy in a subgroup of CD 
patients eligible for treatment discontinuation. 
In another scenario, the physician’s objective is to evaluate the disease activity for 
continuation or escalation of treatment. As we here found a high sensitivity for detecting 
endoscopic activity, we suggest that increased BWT on GIUS may be sufficient. By adding 
colour Doppler in pathologically thickened sections as well as faecal calprotectin in 
sonography-detected colitis, the diagnostic accuracy may be further improved. Consequently, 
implementation of GIUS in follow-up examinations could potentially reduce the need for 
ileocolonoscopic examinations, enabling better allocation of endoscopic resources. 
The study has potential limitations. The endoscopists have various clinical experience which 
could lead to different assessments of endoscopic activity, and no formal consensus on SES-
CD calculation were performed. Still, this may be of less importance as endoscopic remission 
and activity was strictly defined. The interobserver analyses were performed on a limited 
number of patients due to practical reasons. Future studies should also investigate whether 
implementation of GIUS in outpatient clinic could provide additional decision-making effects 
compared to standard follow-up examinations. Finally, as our study was performed on a 
hospital cohort, the findings may not be applicable in a primary care setting. 
In conclusion, GIUS is an accurate surrogate marker of endoscopic activity in Crohn’s 
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Figure 1: Terminal ileum in endoscopic (a) and sonographic (b) remission. Bowel wall 














Figure 2: Terminal ileitis with oedema and large ulcerations at ileocolonoscopy (a), identified 















Figure 3: Neoterminal ileum with a solitary aphthous lesion at endoscopy (a). There were 
normal findings at ultrasonography (b). The arrow shows the neoterminal ileum on GIUS.   
 
  
Tables:   
 
 Activity group  Remission 
group 
 





Age, year  42 (18-78)  38 (18-83) 0.554 a 
Years of sickness  10 (0-44)  8 (1-40) 0.108 a 
Height, metre  1.7 (0.09)  1.7 (0.1) 0.368 
Weight, kg  72 (43.5-112)  71 (47-120) 0.441 
Body mass index (BMI)  24.2 (17.8-34.6)  24.2 (17.9-35.8) 0.932 a 
Haemoglobin, g/dL   13.8 (9.1-16.8)  14.0 (11.1-17.5)) 0.261 
Leucocyte count, 109/L 6.4 (2.5-15.1)  5.2 (2.2-11.1) 0.061 a 
Platelet count, 109/L  284.5 (156-513)  272.5 (118-439) 0.277 
C-reactive protein (CRP) 2 (0-96)  1 (0-16) 0.039a * 
Albumin, mg/L  45 (32-54)  46 (40-53) 0.067 
Calprotectin, mg/kg 78 (7.5-2178)  18 (7.5-135.5) <0.001a * 
Harvey Bradshaw Index (HBI) 3.0 (0-20)  1.8 (0-9) 0.011a * 
*Significant differences between the groups 
a Mann-Whitney U test  
 
Table 1: Demographical, biochemical and clinical data of included CD patients (continuous 
parameters). The patients are designated to the activity- or remission groups according to 
endoscopic activity (SES-CD >0 or SES-CD = 0, respectively). There were no significant 
differences (Student’s t test/ Mann-Whitney U test) between the groups except for C-reactive 
protein, calprotectin and Harvey Bradshaw index.   
 
  





Female sex,  57 (55.9) 30 (69.8) 0.170 
Age at diagnosis    
 <16 14 (13.7) 7 (16.3) 0.888 
 17-40 69 (67.6) 27 (62.8) 0.710 
 >40 19 (18.6) 9 (20.9) 0.928 
Disease location    
 Ileal (L1) 50 (49.0) 19 (44.2) 0.726 
 Colonic (L2) 12 (11.8) 10 (23.3) 0.131 
 Ileocolonic (L3) 40 (39.2) 14 (32.6) 0.569 
 Upper disease (L4) 8 (7.8) 2 (4.8) 0.386 a 
Disease behaviour     
 non‐stricturing, non‐
penetrating (B1)  
30 (29.4) 29 (67.4) <0.001* 
 Stricturing (B2)  57 (55.9) 8 (18.6) <0.001* 
 Penetrating (B3) 15 (14.7) 6 (14) 1.000 
 Perianal involvement  14 (13.7) 5 (11.6) 0.942 
Previous surgery  54 (52.9) 11 (25.6) 0.004* 
Concomitant treatment    
 Aminosalicylate 11 (10.8) 5 (11.6) 0.544 a 
 Azathioprine 32 (31.4) 16 (37.2) 0.625 
 Methotrexate 7 (6.9) 2 (4.7) 0.468 a 
 Prednisolone 7 (6.9) 0 (0.0) 0.080 a 
 Budesonid  11 (10.8) 2 (4.7) 0.198 a 
 Infliximab 26 (25.5) 16 (37.2) 0.222 
 Adalimumab 13 (12.7) 2 (4.7) 0.119 a 
 Certolizumab 1 (1.0) 0 (0.0) 0.703 a 
 Vedolisumab  12 (11.8) 2 (4.7) 0.154 a 
*Significant differences between the groups 
a Fisher exact test 
 
 
Table 2: Demographical and clinical data of included CD patients (categorical parameters). 
The patients are designated to the activity- or remission groups according to endoscopic 
activity (SES-CD >0 or SES-CD = 0, respectively). There were no significant differences 
(Chi-square- and Fischer exact test) between the groups except for disease behaviour (B1 and 






































































































* Data presented as percentages, with the number of cases used for calculation in parentheses.  
⁑ Agreement between ileocolonoscopy and the included parameters using Cohen’s Kappa 
a Bowel wall thickness >3 mm 
b Bowel wall thickness >4 mm 
c Colour Doppler score of 1 or 2 (added on bowel segments with BWT >3 mm) 
d Harvey Bradshaw Index >4 points 
e C-reactive protein >4 mg/L 
f Calprotectin >50 mg/kg 
g Calprotectin after exclusion of terminal ileitis 
h BWT >3mm or Calprotectin >50 mg/kg 
Table 3: The ability of ultrasonography, clinical- and biochemical tests to differentiate between patients in endoscopic remission and activity
 
